Thomas Plavac, MD
Cardiovascular Disease · Meridian, MSNPI 1649272782
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,123 of the $9,419 with a category attached, or 86.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 374 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Medtronic$1K
- Penumbra, Inc.$1K
- Abiomed$922
- Johnson & Johnson$724
- AstraZeneca$528
- plus $3K from 28 others
What the payments were for
- Travel & lodging$1,23613%
- Food & beverage$8,12386%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 101 | $1,458 |
| Medtronic(2 entities) | 53 | $1,457 |
| Penumbra, Inc. | 6 | $1,154 |
| Abiomed | 19 | $922 |
| Johnson & Johnson | 35 | $724 |
| AstraZeneca | 14 | $528 |
| E.r. Squibb & Sons, L.L.C. | 28 | $523 |
| Merck | 23 | $496 |
| Amgen | 18 | $397 |
| Pfizer | 18 | $323 |
| Inari Medical, Inc. | 2 | $309 |
| Lexicon Pharmaceuticals, Inc. | 4 | $169 |
| Astellas Pharma US Inc | 6 | $130 |
| Esperion Therapeutics, Inc. | 6 | $121 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $79 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Lilly USA, LLC | 2 | $43 |
| Cvrx, Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $38 |
| Abbott | 2 | $37 |
| Bayer | 2 | $35 |
| W. L. Gore & Associates, Inc. | 1 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Silk Road Medical, Inc. | 1 | $28 |
| Boston Scientific | 1 | $22 |
| United Therapeutics Corporation | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$936
- FLOWTRIEVER CATHETER, S$309
- CT THROMBECTOMY SYSTEM KIT$309
- FARXIGA$249
- XARELTO$235
- Inpefa$125
- ELIQUIS$124
- Repatha$124
How this compares
$9,419 in reported general payments places this provider in the 70th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 561 | $504,188 |
| XareltoRivaroxaban | 137 | $146,456 |
| EntrestoSacubitril/Valsartan | 109 | $140,827 |
| BrilintaTicagrelor | 126 | $108,706 |
| FarxigaDapagliflozin Propanediol | 82 | $65,673 |
| Repatha SureclickEvolocumab | 70 | $50,024 |
| JardianceEmpagliflozin | 23 | $24,738 |
| Praluent PenAlirocumab | 26 | $18,853 |
| Rosuvastatin Calcium | 1,216 | $13,193 |
| Doxazosin Mesylate | 388 | $8,933 |
| Metoprolol Succinate | 558 | $8,741 |
| Losartan Potassium | 836 | $8,615 |
| SotalolSotalol Hcl | 390 | $7,850 |
| Nifedipine ErNifedipine | 279 | $7,789 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $7,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $323 | $504,188561 claims |
| AstraZenecaBrilinta, Farxiga | $528 | $174,379208 claims |
| Johnson & JohnsonXarelto | $724 | $146,456137 claims |
| NovartisEntresto | $1,458 | $140,827109 claims |
| Boehringer IngelheimJardiance | $30 | $24,73823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Meridian
- Larry HaileyMeridian$10K
- Charles DavenportMeridian$9K
- Randall JoransenMeridian$7K
- Usman SalahuddinMeridian$5K
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.